Clinical Trials Logo

Carbon Monoxide Poisoning clinical trials

View clinical trials related to Carbon Monoxide Poisoning.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05110820 Completed - Clinical trials for Carbon Monoxide Poisoning

Quantitative Assessment of Pupillary Light Reflex in Acute Carbon Monoxide Poisoning

Start date: August 1, 2019
Phase:
Study type: Observational

Neurological complications after acute carbon monoxide (CO) poisoning can range from transient headache or dizziness to cognitive dysfunction, seizure, permanent anoxic brain damages or death. A recent study reported that a lack of standard pupillary light reflex (sPLR), assessed using a pen light, was a predictor of 30-day neurological sequelae in patients with CO poisoning. Given that the basic sPLR has a poor inter-rater reliability, more objective and quantitative methods are required in the assessment of PLR. An automated pupillometer has been used in the intensive care unit to quantitatively assess the PLR. Therefore, we hypothesized that quantitative assessment of PLR might be associated with neurocognitive sequelae after acute CO poisoning. The purpose of this study was to assess the value of quantitative pupillary reactivity (NPi and qPLR) in comparison to that of sPLR in predicting neurocognitive outcome at 1 month after acute CO poisoning.

NCT ID: NCT05088005 Completed - Biomarkers Clinical Trials

Prognostic Biomarkers in CO Poisoning

Start date: January 1, 2020
Phase:
Study type: Observational

Mitochondrial and oxidative stress participate in the pathogenic mechanisms of carbon monoxide (CO)-induced toxicity. Thus, serum indicators of mitochondrial and oxidative stress could be useful for predicting neurocognitive prognosis of post-CO poisoning. This prospective observational study of consecutive patients requiring hyperbaric oxygen therapy (HBO2) for acute CO poisoning measured serum biomarkers of mitochondrial (growth differentiation factor 15 [GDF15]; fibroblast growth factor 21 [FGF21]) and oxidative (8-Oxo-2'-deoxyguanosine [8-OHdG] and malondialdehyde [MDA]) stresses at arrival at the emergency department (0 h), and at 24 h and 7 days after HBO2 completion. We evaluated neurocognitive outcomes using the Global Deterioration Scale (GDS; favorable [1-3 points] or poor [4-7 points] outcomes).

NCT ID: NCT04832256 Completed - Fresh Flow Clinical Trials

Effects of Different Fresh Gas Flows on Carboxyhemoglobin Levels

Start date: January 1, 2016
Phase:
Study type: Observational

To observe the effect of different fresh flows (1 L / min and 4 L / min) on the carboxyhemoglobin level non-invasively and continuous measurement and to determine the contribution of smoking to the intraoperative carbon monoxide accumulation.

NCT ID: NCT04656912 Completed - Clinical trials for Carbon Monoxide Poisoning

Hyperbaric Oxygen Therapy Initiation Time in Acute Carbon Monoxide Poisoning

Start date: September 1, 2020
Phase:
Study type: Observational

Hyperbaric oxygen therapy (HBO2) is recommended for symptomatic patients within 24 h of carbon monoxide (CO) poisoning. However, previous major studies found significantly better outcomes with HBO2 in patients treated within 6 h. Currently, there is no consensus on a CO poisoning-to-HBO2 interval that would not be beneficial. Therefore, the investigators aimed to evaluate the difference in therapeutic effect depending on the poisoning-to-HBO2 interval after CO exposure in patients with acute CO poisoning who received HBO2 within 24 h. The investigators compared the neurocognitive outcomes of patients according to HBO2 time intervals based on the outcomes of patients treated within 6 h (control group) with propensity score matching using the CO poisoning registry of our hospital.

NCT ID: NCT04419298 Completed - Myocardial Injury Clinical Trials

Cardiac Magnetic Resonance Image (CMR) in Acute Carbon Monoxide (CO) Poisoning

Start date: August 1, 2017
Phase:
Study type: Observational

Previous report showed that 37% of patients with moderate to severe carbon monoxide (CO) poisoning experienced a myocardial injury, defined as elevated cardiac enzyme [creatine kinase, CK-MB, and cardiac troponin I (TnI)] or ischemic electrocardiogram (ECG) change. In other study, 24% of the patients with the myocardial injury after CO poisoning died during a median follow-up of 7.6 years. The myocardial injury was the major predictor of mortality. In addition, in the Taiwanese nationwide population-based cohort study, CO poisoning itself reported as a higher risk of a major adverse cardiovascular event. According to the previous study of investigators, among CO poisoned patients with myocardial injury, 74.4% of patients experienced CO-induced cardiomyopathy. All CO-induced cardiomyopathy recovered to normal status. In this situation, there is no definite approved reason why more cardiovascular events are occurred in CO poisoned patients with myocardial injury during long term follow-up period despite normalization of CO-induced elevated TnI and cardiac dysfunction. Two image cases related to cardiac magnetic resonance imaging (CMR) in acute CO poisoning previously reported. One image case reported that patient had mildly depressed left ventricular (LV) systolic function with hypokinesis of the anterior wall and regional akinesis of the inferior wall on the transthoracic echocardiography performed during hospitalization and late gadolinium-enhancement (LGE) images of CMR demonstrated multiple focal areas of high signal consistent with myocardial necrosis or fibrosis. Another image case reported an image case that in CMR, inferolateral mid-wall myocardial fibrosis, which was defined as LGE, was present despite the setting of a completely normal echocardiogram at 4-month follow-up in CO poisoned patients. Therefore, the investigators evaluate prevalence (frequency of LGE positive) and patterns (involved LV wall and range of LGE positive) of myocardial fibrosis (LGE positive) in acute CO-poisoned patients during acute (within seven days after CO exposure) and chronic phase (at 4-5 months after CO exposure) and whether LGE positive developed in acute phase have been changed through cardiac MRI performed at chronic phase. The investigators also evaluate LV ejection fraction and global longitudinal strain in transthoracic echocardiography performed at the ED (baseline) and within seven days (follow-up). The investigators also assessed the association between neurocognitive outcomes using the global deterioration scale (at 1, 6, and 12 months after CO exposure) and the presence of LGE positive.

NCT ID: NCT03926494 Completed - Coma Clinical Trials

Carbon Monoxide-induced Coma: Prognostic Factors

Coma-CO
Start date: May 1, 2019
Phase:
Study type: Observational

The primary objective of the study is to determine prognostic factors for hospital-mortality following carbon monoxide (CO)-induced coma. The secondary objective is to determine prognostic factors of CO related cognitive sequelae, at the time of hospital discharge.

NCT ID: NCT03669848 Completed - Clinical trials for Carbon Monoxide Poisoning

Is Transcutaneous Carbon Monoxide Saturation of E-cigarette Users Comparable to That of Smokers?

COVAP
Start date: September 12, 2018
Phase:
Study type: Observational

Suspicions of carbon monoxide poisoning that lead to the treatment of victims are numerous. Measurement of transcutaneous carbon monoxide saturation (SpCO) is a useful diagnostic and triage tool for victims and the toxic threshold is clearly defined for both non-smokers (SpCO> 5%) and smokers ( SpCO> 10%). Currently, the use of e-cigarettes is democratizing. Unfortunately, the threshold for toxic SpCO is not defined for this patient profile. The risk is treating in excess or worse than underestimating carbon monoxide poisoning in e-cigarette users who would be exposed to carbon monoxide exposure.

NCT ID: NCT03342209 Completed - Clinical trials for Environmental Exposure

Utility of High Flow Nasal Cannula in CO Toxicity

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

determination of the half-life of COHb in CO-poisoned patients with high flow nasal oxygen therapy in the ED.

NCT ID: NCT03030833 Completed - Clinical trials for Carbon Monoxide Poisoning

Dysfunctional Hemoglobin Pulse Oximetry

Start date: February 6, 2017
Phase: N/A
Study type: Observational

The purpose of the study is to assess device performance in the presence of carbon monoxide.

NCT ID: NCT02950701 Completed - Clinical trials for Carbon Monoxide Intoxication

Suspected Cases of Carbon Monoxide Poisoning

Start date: November 2016
Phase:
Study type: Observational

The purpose of this study is to collect non-invasive opportunity sample data in suspected or known cases of carbon monoxide poisoning.